What are the differences between Olaparib and Niraparib?

Olaparib (Olaparib) and niraparib (Niraparib) are both PARP inhibitor targeted drugs, mainly used to treat ovarian cancer, breast cancer, prostate cancer and other tumor types carrying BRCA mutations. Although they are similar in mechanism, they both block the DNA repair pathway of cancer cells by inhibiting the activity of PARP enzyme, causing "lethal synthesis" of tumor cells. However, there are obvious differences between the two in terms of indications, pharmacokinetics, clinical manifestations and side effects.

Olaparib and niraparib have different indications. Lynparza was initially used to treat BRCA advanced ovarian cancer, and has since been expanded to BRCA mutation-related breast cancer, prostate cancer and pancreatic cancer, and can be used for Maintenance treatment; niraparib is mainly used for recurrent ovarian cancer and some BRCA negative patients, and its efficacy is also recognized independent of BRCA mutation status. Therefore, from the perspective of the clinically applicable population, niraparib has wider indications, and olaparib performs more prominently in BRCA mutation-positive patients.

There are also differences in the way they are metabolized and how they are taken. Olaparib is usually taken twice a day (e.g. 300mg, twice a day), while niraparib is taken once a day (generally 300mgonce a day), which may have an impact on patients' medication compliance. In addition, olaparib is mainly metabolized by the liver (CYP3A pathway), while niraparib is mainly metabolized in the body through non-enzymatic pathways, which means that niraparib has a lower risk of drug interactions when combined with other drugs.

In terms of side effects, niraparib is more likely to cause hematological toxicity, such as thrombocytopenia, anemia, etc., especially in patients with low body weight or low baseline platelet levels; while common adverse reactions of olaparib include nausea, fatigue, anemia, etc. Generally speaking, both drugs have their own advantages and disadvantages. Doctors usually decide which PARP inhibitor to use based on the patient's specific condition, genetic status, tolerance, and combined medications. Choosing the right drug can not only improve the efficacy, but also better protect the patient's quality of life.

Reference materials:https://www.lynparza.com/